Introduction {#Sec1}
============

DNA repair pathways play key roles in maintaining genomic stability and influence carcinogenesis and tumour biology. Impaired DNA repair also impacts upon response to DNA damaging radiotherapy and chemotherapeutics \[[@CR1]\]. Poly\[ADP-ribose\] polymerase (PARP) is a key DNA repair factor. PARP is an abundant, highly conserved, cell signalling protein that exclusively catalyses poly ADP-ribosylation of DNA-binding proteins, thereby modulating their activity. PARP is essential for DNA single strand break (SSB) repair \[[@CR2]\], a sub-pathway related to base excision repair. Loss of PARP are associated persistent SSBs that get converted to DNA double-strand breaks (DSBs) following collapse of replication forks. DSBs generated during the S-phase of the cell cycle is repaired via homologous recombination (HR) pathway whereas DSBs generated outside the S-phase are processed through the error-prone non-homologous end joining (NHEJ) repair pathway. PARP1 is also involved in HR and NHEJ pathways \[[@CR3]--[@CR5]\].

The BRCA genes encode BRCT repeat containing proteins that facilitate the efficient resolution of DSBs generated during the S-phase through HR. Cells lacking functional BRCA proteins are deficient in HR, and thus dependent on the more error-prone NHEJ pathway. This transition results in chromosomal instability and drive a malignant phenotype. Women carrying deleterious germline mutations in the BRCA1 and BRCA2 genes have a high risk of developing breast and ovarian cancers. It was recently demonstrated that HR impaired BRCA deficient cells are hypersensitive to PARP inhibitors. Although the precise mechanism for synthetic lethality is not fully known, SSB repair inhibition may result in the formation and accumulation of toxic DSBs at replication forks in BRCA deficient cells and induces synthetic lethality. Emerging data from clinical trials using PARP inhibitors in *BRCA* deficient breast and ovarian tumours has provided promising evidence that synthetic lethality by targeting PARP has clinical potential \[[@CR6]--[@CR9]\].

PARP1 is the main member of the PARP family. PARP1 induce cell survival through DNA repair; however during apoptosis, PARP1 is cleaved into two fragments by caspases resulting in its inactivation \[[@CR10]\]. This caspase-mediated PARP1 inactivation suggests that blocking PARP1 activity is vital for the proper function of the apoptotic machinery by the ensuing DNA fragmentation \[[@CR11]\]. Although overexpression of PARP1 is found in different primary human tumours compared to normal tissue counterparts \[[@CR12]--[@CR14]\], the biological and clinical significance of PARP1 protein expression in breast cancer remains to be fully elucidated. In this study we have assessed the expression of PARP1 (both cleaved and non-cleaved forms) in a large and well-characterised clinically annotated series of breast cancer with a long term follow-up data. Its association with clinicopathological variable, molecular variables and patients outcome was evaluated.

Materials and methods {#Sec2}
=====================

Study patients {#Sec3}
--------------

This retrospective study was conducted using two independent cohorts of patients; an initial biomarker discovery cohort consisting of 1902 ER-negative and ER-positive patients and a control cohort of 43 breast cancer from patients with confirmed *BRCA*1-germline mutations. The discovery cohort comprises a well-characterised consecutive series of early stage (TNM Stage I--III) sporadic primary operable invasive breast carcinoma from patients (age ≤70 years) enrolled into the Nottingham Tenovus Primary Breast Carcinoma Series that presented at Nottingham City Hospital between 1989 and 2004 (*n* = 1,502) and managed in accordance to a uniform protocol. Patients' clinical history, tumour characteristics, information on therapy and outcomes are prospectively maintained. Outcome data include survival status, survival time, cause of death and development and time to local and regional recurrence and distant metastasis (DM). Breast cancer specific survival (BCSS) is defined as the time (in months) from the date of primary surgery to the date of breast cancer-related death. Disease free survival (DFI) is defined as the time (in months) from the date of primary surgery to the appearance of a recurrence. In this study, overall relapse free survival was not considered in the analysis as the development of locoregional recurrence is influenced by local management factors and tumour stage, which may confound the effect of the primary tumour biology.

Tissue arrays and immunohistochemistry {#Sec4}
--------------------------------------

Tumour samples were arrayed as previously described \[[@CR15]\]. In brief, tissue cores with a diameter of 0.6 mm were punched from the representative tumour regions of each donor block. Cores were precisely arrayed into a new recipient paraffin blocks (TMA) using a tissue microarrayer (Beecher Instruments). Immunohistochemical staining was performed on 4 μm thick sections using Novolink polymer detection system (Leica Biosystems, RE7150-K), composed of Peroxidase Block, Post Primary Block, Novolink Polymer, DAB chromogen and substrate buffer and Novolink haematoxylin. Table [1](#Tab1){ref-type="table"} shows the dilution, source and clone of antibodies used in this study. Briefly, tissue slides were deparaffinised with xylene and rehydrated through 3 changes of alcohol. Antigen retrieval (except for EGFR and HER2) was performed in citrate buffer (pH 6.0) for 20 min using a microwave oven. Endogenous peroxidase activity was blocked by Peroxidase Block for 5 min. Slides were washed with Tris-Buffered Saline (TBS, pH 7.6), followed by application of Protein Block for 5 min. Following another TBS wash, primary antibody, optimally diluted in Leica antibody diluent (RE7133), was applied and incubated for 60 min. Slides were washed with TBS followed by incubation with Post Primary Block for 30 min followed by a TBS wash. Novolink polymer was applied for 30 min. DAB working solution made up of 1:20 DAB chromogen in DAB substrate buffer was prepared and applied for 5 min. Slides were counterstained with Novolink haematoxylin for 6 min, dehydrated and coverslipped. Negative (omission of the primary antibody) and Positive controls were included according to manufacturer datasheet of each antibody. Table [1](#Tab1){ref-type="table"} shows the different biomarkers included in this study. Antibody specificity was tested using Western blotting and correct sized band was obtained for the different proteins. HER2 status was also confirmed using in situ hybridisation in borderline cases. Ki67 was assessed using full face section as previously described \[[@CR17]\].Table 1Source, dilution and pre-treatment of antibodies usedAntibodyDilutionSource/clonePretreatment/solutionCut-offHormone receptor ER^a^1:200DAKO, ID5Microwave, citrate pH 6.0≥1 %DNA damage repair molecules PARP1 (Cleaved)1:1,000Abnova, A6.4.12Microwave, citrate pH 6.0\>200 H-score PARP1 (Non-cleaved)1:1,000BD Pharmingen, 7D3-6Microwave, citrate pH 6.0\>10 H-score RAD511:70Abcam, mouse polyclonalMicrowave, citrate pH 6.0 BRCA11:150Oncogene research, MS110Microwave, citrate pH 6.0\>100 H-score Ku70/Ku801:2,500Abcam, mouse monoclonalMicrowave, citrate pH 6.0\>90 H-score PIASγ1:50Abcam, anti E3 (ab61405)Microwave, citrate pH 6.0\>160 H-scoreBRCA1 transcriptional suppressor molecule ID41:300Abcam, ab 20988- 100Microwave, citrate pH 6.0\>12 H-scoreEGFR family members EGFR1:30Zymed, 31G7Proteinase K\>10 % c-erbB-2 (HER2)1:250DAKO, c-erbB-2None3+ (2+ with CISH)Cell cycle, proliferation and apoptosis related proteins p531:50Novocstra, DO7Microwave, citrate pH 6.0\>10 % MDM21:50Novocastra, IB10Microwave, citrate pH 6.0≥10 % Ki-67/clone MIB1^a^1:100DAKO, M7240Microwave, citrate pH 6.0\>10 % Bcl21:100DAKO, 124Microwave, citrate pH 6.0\>10 % CHK11:150Abcam, rabbit polyclonalMicrowave, citrate pH 6.0\>30 H-score CK5/61:100Boehringer biochemica, D5/16134Microwave, citrate pH 6.0\>10 % CK141:100Novocastra, LL002Microwave, citrate pH 6.0\>10 % CK171:20Abcam, E3Microwave, citrate pH 6.0\>10 %^a^Performed on full face formalin fixed, paraffin embedded tissue sections

### Evaluation of immunohistochemical staining {#Sec5}

Two cores were evaluated from each tumour. Each core was scored individually and the mean of the two readings was calculated. If one core was uninformative, the overall score applied was that of the remaining core. Assessment of staining was based on a semi-quantitative approach using a modified histochemical score (H-score) was used which includes an assessment of both the intensity of staining and the percentage of stained cells \[[@CR16]\]. For the intensity, a score index of 0, 1, 2 and 3 corresponding to negative, weak, moderate and strong staining intensity was used and the percentage of positive cells at each intensity was estimated subjectively. A final score of 0--300 is the product of both the intensity and the percentage. Cut-off of expression of PARP1 and ID4 was chosen based on the median: H-score of 200 for PARP1 cleaved (PARP1c) and 10 for PARP1 non-cleaved (PARP1nc). Cut-offs of the other biomarkers included in this study (Table [1](#Tab1){ref-type="table"}) were chosen as per previous publications \[[@CR17]--[@CR19]\].

### Statistical analysis {#Sec6}

Statistical analysis was performed using SPSS 21.0 statistical software. Univariate and multivariate analyses were performed by Chi-squared test, Log rank and Cox regression analysis, respectively. Survival curves were analysed by the method of Kaplan--Meier (Kaplan and Meier, 1958). A *p* value \< 0.01 was considered significant. This study complied with reporting recommendations for tumour marker prognostic studies (REMARK) criteria.

Results {#Sec7}
=======

In this study, the expression of PARP1 protein including the non-cleaved/active (PARP1nc) and the cleaved (PARP1c) forms were assessed immunohistochemically and correlated with clinicopathological variables, expression of key biomarkers with relevance to breast cancer, DNA repair markers and patient outcome. Both PARP1 protein forms (PARP1c and PARP1nc) were observed only in the nuclei with no cytoplasmic or membranous expression. Expression of PARP1c and PARP1nc were observed in the normal parenchymal cells of the entrapped normal tissue but their expression was upregulated in malignant cells (Fig. [1](#Fig1){ref-type="fig"}). Only nuclear expression in the malignant cells was considered in this study Fig. [2](#Fig2){ref-type="fig"}.Fig. 1Expression of **a** PARP1 non-cleaved **b** PARP1 cleaved protein expression. Normal breast tissue showing weak expression with tumour showing strong expression ×20Fig. 2Cell cycle regulators (p21 and p27), BRCA1 transcriptional suppressor marker (ID4) and DNA repair proteins \[PARP1 (cleaved), RAD51, Ku70/80, PIASγ and CHK1\] immunohistochemical expressions in invasive breast carcinomas: **a** P21 positive IHC expression, **b** P27 positive IHC expression, **c** ID4 positive IHC expression, **d** PARP1 (cleaved) positive IHC expression, **e** RAD51 positive IHC expression, **f** Ku70/80 positive IHC expression, **g** PIASγ positive IHC expression and **h** CHK1 positive IHC expression (×400)

In unselected sporadic breast cancer, reduced or absent expression of PARP1c was observed in 15.4 % while negative expression of PARP1nc (active form) was observed in 51.3 % (Table [2](#Tab2){ref-type="table"}). There was a highly significant correlation between both proteins (*p* \< 0.001). PARP1nc was negative in 2/43 (4.7 %) *BRCA*1 germline-mutated tumours whereas PARP1c was negative in 5/43 (10.4 %, Table [2](#Tab2){ref-type="table"}) tumours.Table 2Immunohistochemical expression of PARP1 cleaved and non-cleaved in breast cancerPARP1 non-cleaved *n* (%)PARP1 cleaved *n* (%)NegativePositive*p* valueNegativePositive*p* valueUnselected sporadic series552 (51.3)524 (48.7)N/A194 (15.4)1075 (84.6)N/ABRCA1-mutated tumours2 (4.7)41 (95.3)5 (10.4)38 (79.2)Classes ERNegative140 (49.6)142 (50.4)NS59 (18.9)253 (81.1)**0.041**Positive405 (51.7)379 (48.3)134 (14.1)815 (85.9) HER2Negative469 (52.1)432 (47.9)NS165 (15.3)913 (84.7)NSPositive63 (46.3)73 (53.7)22 (14.0)135 (86.0) Triple negativeNo446 (52.1)410 (47.9)NS145 (14.1)883 (85.9)**0.030**Yes90 (47.6)99 (52.4)42 (20.0)168 (80.0) Basal phenotypeNo414 (52.0)382 (48.0)NS141 (14.8)810 (85.2)NSYes138 (48.9)132 (51.1)53 (16.8)263 (83.2)Bold values indicate significance*ER* oestrogen receptor, *NS* not significant

Association with clinicopathological and molecular variables sporadic breast cancer {#Sec8}
-----------------------------------------------------------------------------------

### PARP1nc {#Sec9}

PARP1nc expression was positively associated with premenopausal younger age patients and higher tumour grade with nuclear pleomorphism, mitosis and a poorer prognosis (Table [3](#Tab3){ref-type="table"}). There was no association with histological tumour type, vascular invasion, size or stage.Table 3Relationship between PARP1 cleaved and non-cleaved with clinicopathological parametersVariablesPARP1 non-cleavedPARP1 cleavedNegative *n* (%)Positive *n* (%)*p* valueNegative *n* (%)Positive *n* (%)*p* valueMenopausal status Pre182 (33.2)216 (41.7)**0.004**65 (33.5)409 (38.5)NS Post366 (66.8)302 (58.3)129 (66.5)653 (61.5)Age \<50163 (29.7)193 (36.9)**0.012**61 (31.4)365 (34)NS ≥50386 (70.3)330 (63.1)133 (68.6)710 (66)Tumour size ≤2 cm279 (51.2)240 (46.1)NS96 (50)523 (48.8)NS \>2 cm266 (48.8)281 (53.9)96 (50)548 (51.2)Tumour stage 1346 (62.9)310 (59.5)NS129 (66.5)634 (59.2)NS 2159 (28.9)164 (31.5)51 (26.3)342 (31.9) 345 (8.2)47 (9.0)14 (7.2)95 (8.9)Tumour grade 1113 (20.7)69 (13.3)**0.001**32 (16.7)180 (17.9)NS 2180 (33)163 (31.3)61 (31.8)368 (34.5) 3253 (46.3)288 (55.4)99 (51.6)519 (48.6)Tubule formation 135 (6.7)24 (4.7)NS11 (5.9)62 (6)NS 2181 (34.6)160 (31.6)57 (30.3)336 (32.6) 3307 (58.7)323 (63.7)120 (63.8)634 (61.4)Pleomorphism 114 (2.7)10 (2)**\<0.001**1 (0.5)29 (2.8)NS 2233 (44.6)168 (33.1)76 (40.4)404 (39.2) 3275 (52.7)329 (64.9)111 (59)598 (58)Mitosis 1201 (38.4)145 (28.6)**0.001**66 (35.1)373 (36.1)NS 2103 (19.7)95 (18.7)30 (16)200 (19.4) 3219 (41.9)267 (52.7)92 (48.9)459 (44.5)Vascular invasion Negative185 (34)174 (33.5)NS65 (34)355 (33.2)NS Positive359 (66)346 (66.5)126 (66)714 (66.8)NPI groups Good190 (34.9)134 (25.7)**0.005**63 (32.8)326 (30.4)NS Moderate269 (49.4)295 (56.6)94 (49)566 (52.8) Poor86 (15.8)92 (17.7)35 (18.2)179 (16.7)Bold values indicate significance*NS* not significant

Expression of PARP1nc showed positive association with the expression of other DNA repair proteins involved in DDR (BRCA1, RAD51, check-point proteins, (CHK1 and CHK2) PIASγ and DNA PK), together with the proliferation marker Ki67 and p53 (Table [4](#Tab4){ref-type="table"}). No association was observed with ER, HER2, the *BRCA*1 transcriptional suppressor ID4, BARD1, BRCA2, Ku70/Ku80 or APE1.Table 4Relationship between PARP1 cleaved and non-cleaved with other tumour markersVariablesPARP1 non-cleavedPARP1 cleavedNegative no. (%)Positive no. (%)*p* valueNegative no. (%)Positive no. (%)*p* valueAPE1Negative31 (16.2)36 (15.9)NS16 (19.8)59 (14.4)NSPositive160 (83.8)190 (84.1)65 (80.2)352 (85.6)BARD1Negative299 (87.4)314 (88.2)NS115 (89.8)620 (86.8)NSPositive43 (12.6)42 (11.8)13 (10.2)86 (12.2)BRCA1Negative218 (51.8)178 (41.9)**0.004**74 (50.3)370 (43.3)NSPositive203 (48.2)247 (58.1)73 (49.7)485 (56.7)BRCA2Negative348 (92.6)333 (92.5)NS111 (92.5)666 (92.4)NSPositive28 (7.4)27 (7.5)9 (7.5)55 (7.6)RAD51Negative275 (68.9)191 (48.1)**\<0.001**107 (84.3)391 (53.8)**\<0.001**Positive124 (31.1)206 (51.9)20 (15.7)336 (46.2)CHK1Negative360 (79.3)323 (69.3)**\<0.001**127 (84.7)607 (71.9)**\<0.001**Positive94 (20.7)143 (30.7)23 (15.3)237 (28.1)Ku70/Ku80Negative78 (17.3)65 (14.6)NS61 (38.4)101 (12.5)**\<0.001**Positive373 (82.7)379 (85.4)98 (61.6)708 (87.5)PIASγNegative156 (33.3)74 (15.7)**\<0.001**80 (50)164 (18.3)**\<0.001**Positive113 (66.7)396 (84.3)80 (50)730 (81.7)DNA-PKcsNegative81 (25.9)38 (11.3)**\<0.001**44 (36.7)88 (13.8)**\<0.001**Positive232 (74.1)299 (88.7)76 (63.3)552 (86.2)Ki67Negative145 (35.5)122 (28.2)**0.022**49 (33.6)284 (33.1)NSPositive263 (64.5)311 (71.8)97 (66.4)573 (66.9)ID4Negative424 (87.4)410 (89.5)NS148 (85.1)839 (89.4)NSPositive61 (12.6)48 (10.5)26 (14.9)99 (10.6)P53Negative413 (77.1)328 (65.3)**\<0.001**137 (75.3)748 (71.2)NSPositive123 (22.9)174 (34.7)45 (24.7)302 (28.8)Bold values indicate significance*NS* not significant

Although there was a positive association between PARP1nc and BRCA1, both proteins showed opposite association with proliferation and with other DNA repair proteins; the majority of PARP1nc^+^/BRCA1^−^ was associated with high expression of DNA PK (*p* = 0.003), p53 (*p* \< 0.001), and ki67 (*p* \< 0.001) compared with PARP1nc^−^/BRCA1^+^ tumours (Table [5](#Tab5){ref-type="table"}). Positive CHK1 expression (*p* = 0.004) and negative expression of PIASγ (*p* = 0.013) were associated with PARP1nc^−^/BRCA1^+^ tumours.Table 5Relationship between PARP1 non-cleaved and BRCA1 with DNA repair markersMarkerPARP1nc^+^/BRCA1^−^ *n* (%)PARP1nc^−^/BRCA1^+^ *n* (%)*p* valueCHK1Negative137 (52.3)125 (47.7)**0.004**Positive21 (32.3)44 (67.7)DNA-PKcsNegative12 (32.4)25 (67.6)**0.003**Positive116 (59.2)80 (40.8)P53Negative99 (37.1)168 (62.9)**\<0.001**Positive78 (69.0)25 (31.0)PIASγNegative25 (36.2)44 (63.8)**0.013**Positive143 (53.0)127 (47.0)Ki67Negative25 (29.8)59 (70.2)**\<0.001**Positive130 (61.3)82 (47.6)Bold values indicate significance

When the series was classified based on ER expression, positive correlations between PARP1nc and PIASγ, DNA-PKcs and p53 were seen in both ER + and ER− tumours while positive associations with BRCA1, RAD51, CHK1 and CHK2 were seen only in ER+ but not in the ER− tumours (Table [6](#Tab6){ref-type="table"}). In ER− tumours, associations between PARP1nc and ki67 (positive) and ID4 (negative) were observed but not in the ER+ tumours.Table 6Relationship between DNA repair biomarkers PARP1ceaved and non-cleaved with biomarkers in ER-positive and negative populationsVariablesER-positiveER negativeNegative *n* (%)Positive *n* (%)*p* valueNegative *n* (%)Positive *n* (%)*p* valuePARP1 non-cleaved BRCA1Negative138 (44.5)105 (33.9)**0.007**80 (72.1)73 (64)NSPositive172 (55.5)205 (66.1)31 (27.9)41 (36) RAD51Negative197 (67)113 (39.9)**\<0.001**77 (75.5)78 (69.6)NSPositive97 (33)170 (60.1)25 (24.5)34 (30.4) CHK1Negative256 (77.3)216 (64.1)**\<0.001**102 (85)106 (83.5)NSPositive75 (22.7)121 (35.9)18 (15)21 (16.5) CHK2Negative135 (57.4)94 (39.8)**\<0.001**66 (64.1)54 (53.5)NSPositive100 (42.6)142 (60.2)37 (35.9)47 (46.5) PIASγNegative111 (32.5)48 (14.3)**\<0.001**45 (36)26 (19.7)**0.003**Positive231 (67.5)288 (85.7)80 (64)106 (80.3) DNA-PKcsNegative58 (26)25 (10.5)**\<0.001**23 (25.8)13 (13.3)**0.029**Positive165 (74)214 (89.5)66 (74.2)85 (86.7) Ki67Negative126 (42.3)114 (36.4)NS18 (16.7)8 (6.7)**0.019**Positive172 (57.7)199 (63.6)90 (83.3)111 (93.3) ID4Negative323 (91.2)302 (90.1)NS98 (77.2)106 (87.6)**0.031**Positive31 (8.8)33 (9.9)29 (22.8)15 (12.4) P53Negative339 (85.2)277 (75.7)**0.001**73 (53.3)51 (37.5)**0.009**Positive59 (14.8)89 (24.3)64 (46.7)85 (62.5)PARP1 cleaved RAD51Negative70 (81.4)264 (49.1)**\<0.001**37 (90.2)126 (68.9)**0.010**Positive16 (18.6)274 (50.9)4 (9.8)57 (31.1) CHK1Negative85 (82.5)428 (67.9)**0.003**42 (89.4)175 (84.1)NSPositive18 (17.5)202 (32.1)5 (10.6)33 (15.9) CHK2Negative52 (66.7)214 (45.2)**\<0.001**27 (61.4)106 (58.9)NSPositive26 (33.3)259 (54.8)17 (38.6)75 (41.1) PIASγNegative55 (50.9)113 (17)**\<0.001**25 (48.1)51 (22.9)**\<0.001**Positive53 (49.1)552 (83)27 (51.9)172 (77.1) DNA-PKcsNegative26 (34.2)65 (13.6)**\<0.001**18 (40.9)23 (14.3)**\<0.001**Positive50 (65.8)413 (86.4)26 (59.1)138 (85.7) P53Negative112 (87.5)637 (79.8)**0.040**25 (46.3)108 (43.4)NSPositive16 (12.5)161 (20.2)29 (53.7)141 (56.6)Bold values indicate significance

In triple-negative tumour, PARP1nc was positively associated with expression of PIASγ (*p* = 0.002) and p53 (*p* = 0.022, Table [7](#Tab7){ref-type="table"}). No association with the expression of the other markers was found.Table 7Relationship between PARP1 cleaved and non-cleaved with other tumour markers in triple-negative tumourVariablesPARP1 non-cleavedPARP1 cleavedNegative *n* (%)Positive *n* (%)*p* valueNegative *n* (%)Positive *n* (%)*p* valuePIASγNegative35 (42.7)19 (20.7)**0.002**19 (51.4)38 (25)**0.002**Positive47 (57.3)73 (79.3)18 (48.6)114 (75)DNA-PKcsNegative15 (25.9)10 (15.2)NS12 (41.4)16 (14.4)**0.001**Positive43 (74.1)56 (84.8)17 (58.6)95 (85.6)P53Negative48 (54.5)37 (37.8)**0.022**18 (45)71 (42.5)NSPositive40 (45.5)61 (62.2)22 (55)96 (57.5)Bold values indicate significance*NS* not significant

### PARP1c {#Sec10}

PARP1c expression was positively associated with the expression of ER, non Triple-Negative tumour (Table [2](#Tab2){ref-type="table"}) and DDR proteins including RAD51, Ku70/80, CHK1, CHK2, DNA-PKcs, and PIASγ (Table [4](#Tab4){ref-type="table"}). No association was observed with the clinicopathological variables (Table [3](#Tab3){ref-type="table"}), expression of other DDR proteins (BRCA1, BRCA2, ID4, BARD1 and APE1), HER2, p53, Ki67 or basal phenotype (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).

When the series was classified based on ER expression, the correlation between PARP1c, and RAD51, PIASγ and DNA-PKcs was seen in both ER+ and ER− cohorts while its associations with CHK1 and p53 were seen only in ER+ but not in the ER− subgroups (Table [6](#Tab6){ref-type="table"}). No association with PARP1c was seen in the ER− subgroup only. In the triple-negative tumour, PARP1c showed positive association with the expression of PIASγ and DNA-PKcs (Table [7](#Tab7){ref-type="table"}).

Combined expression of PARP1nc and PARP1c showed a positive association between PARP1nc +/PARP1c + tumours and BRCA1 nuclear (*p* = 0.027), CHK1 (*p* \< 0.001), DNA-PKcs (*p* \< 0.001), PIASγ (*p* \< 0.001) and p53 (*p* \< 0.001) expression and between PARP1nc^−^/PARP1c^+^ tumours and APE1 (*p* = 0.016) and KU70/KU80 (*p* \< 0.001) expression.

Association with patient outcome {#Sec11}
--------------------------------

Although no association between PARP1 and patient outcome (BCSS or DFI) was observed in the sporadic breast cancer series or in subgroups based on ER, an association was identified when PARP1nc was combined with BRCA1 (*Χ*^2^ = 13.8, *p* = 0.003). The association between PARP1nc and DFI in the context of BRCA1 expression was observed in BRCA1-positive tumours (*Χ*^2^ = 5.4, *p* = 0.020) (Fig. [3](#Fig3){ref-type="fig"}) but not in the BRCA1-negative tumours. There were no significant associations between PARP1 expression and patient outcome according to systemic treatment.Fig. 3Kaplan--Meier curve for DMFS with respect to PARP1 (non-cleaved) expression in the BRCA1 positive-tumours

Discussion {#Sec12}
==========

This study investigated the expression levels of PARP1 in breast cancer using immunohistochemistry. Our main aim was to better understand the biological role of PARP1 with particular emphasis on DNA repair mechanisms and in the different subgroups of breast cancer. We found that PARP1nc expression was increased in *BRCA*1-mutated tumours compared with invasive sporadic breast cancer. PARP1nc was also correlated with BRCA1 protein expression in sporadic tumours. High nuclear PARP1, incorporating both the cleaved and non-cleaved expression, is found in the majority of BRCA1-associated BCs which is similar to that observed in our study \[[@CR20]\]. Conversely, we have previously shown PARP1nc is relatively low in BRCA1-protein deficient ovarian high grade serous carcinoma \[[@CR21]\].

Inherent defects in DNA repair pathways represent a common feature characterising susceptibility to PARP inhibitors \[[@CR22], [@CR23]\]. This observation was consistent with the hypothesis that loss of one critical DNA repair pathway, such as defect in the HR-pathway in the *BRCA*-mutated hereditary breast cancer, can be compensated by upregulation of the other double-strand DNA repair mechanisms, namely NHEJ or alternative pathway involved in single-stand DNA repair mechanisms including nucleotide (NER) and base (BER) excision repair. Some authors \[[@CR24], [@CR25]\] have therefore postulated that when the BRCA-dependent HR, is lost or dysfunctional, repair shifts toward alternate DNA repair mechanisms which are dependent on PARPs. This hypothesis was also supported by the study of Wang et al. \[[@CR26]\], who demonstrated that PARP1 downregulates *BRCA*2 gene expression and the study of Ossovskaya et al. \[[@CR12]\] who found an inverse relationship between PARP1 and BRCA1 expression in a subset of ovarian cancer. However, current evidence indicates that the specific driver of PARP1 expression in breast cancer still unknown. The application of PARP inhibitors to a subset of sporadic breast cancer namely triple-negative class, was mainly based on (1) the morphologic and molecular similarities between these tumours and *BRCA*1-mutated breast cancers, and (2) the results from preclinical studies demonstrating sensitivity to PARP inhibition in tumours characterised by deficient HR but not by active PARP DNA related pathways or functional status of PARP proteins \[[@CR22], [@CR25]\]. Interestingly, our observation in the *BRCA*1-mutated tumours support the hypothesis that in tumours with defective HR pathways, the expression of PARP1 proteins are upregulated.

However, the expression in the sporadic tumours appeared to be different with positive correlation between PARP1 and most of the other DNA repair proteins. These findings were also observed in the different molecular subclasses of breast cancer including triple-negative tumour. Our findings in addition to the cytoplasmic expression of some DNA repair genes may reflect the complex mechanism of DNA damage repair in sporadic tumours. Consistent with our findings, it has been reported that transfection of the *BRCA*1-mutated cell line with wild-type BRCA1 resulted in a significant increase in BER, whereas knock-down of BRCA1 resulted in decreased BER \[[@CR27], [@CR28]\].

Consistent with our study, associations between PARP1 and PIASγ \[[@CR29]\] and Ku70/80 \[[@CR30], [@CR31]\] have been reported. Another important observation in our study was the lack of association between PARP1 and HER2 and basal-associated marker expression in breast cancer.

It is reported that PARP1c is not active as the protein undergoes apoptotic/necrotic cleavage (caspase cleavage) and that PARP1 cleavage is a hallmark of apoptosis \[[@CR32]\]. However, our results indicate that PARP1c plays an active role in DNA repair with significant association with other DNA repair proteins. This is consistent with a recent study which demonstrated other physiological functions for the cleaved form \[[@CR33]\].

Although PARP1 has been thoroughly investigated and its role in the repair of DNA break is well documented, a model representing its exact role and placing this enzyme in a network with other known DNA damage repair mechanisms remains unavailable. Our results demonstrate that expression of PARP1 proteins are associated with the expression of other DNA repair proteins involved in both HR and NHEJ mechanisms in addition to other markers involved in check-point control and cell proliferation. Our findings also indicate that the association between different DNA damage repair proteins is observed in ER-negative and ER-positive breast cancer suggesting variable activity of the different mechanisms of DNA damage repair in these tumours. Unlike BRCA1, RAD51 and ID4, no association was observed between PARP1 and basal- phenotype in breast cancer \[[@CR34]\]). This lack of association was seen in the whole series as well as in ER-negative and ER-positive tumours. Importantly, if PARP inhibitors are possibly targeting PARP1 proteins, other subsets of sporadic breast cancer rather than basal-like triple-negative class may be potential candidate for this promising therapy.

In conclusion, our results demonstrate the biological role of both forms of PARP1 (cleaved and non-cleaved) in DNA repair in breast cancer based on the significant association with other key DNA damage repair proteins. These associations were not restricted to ER-negative or triple-negative subgroup. This study also emphasises the fact that the mechanisms controlling DNA repair in sporadic breast cancer are complex particularly among the different molecular classes of sporadic breast cancer; emphasising the need for further investigation for the target gene that can be used as predictor for PARP inhibitors.
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